Nureca Limited FY26 Results: Profit Turnaround, ₹100 Crore Capex Approved

Nureca Limited reported a standalone profit of ₹0.297 crore for the year ended March 31, 2026, a significant improvement from a loss of ₹0.668 crore in FY25. Consolidated profit rose to ₹2.08 crore from ₹0.846 crore.

Reader Takeaway: Profitability improved alongside revenue growth, but non-operating investment losses impacted consolidated results.

What just happened

Nureca Limited announced its audited financial results for the fiscal year ended March 31, 2026. The company achieved a standalone profit after tax of ₹0.297 crore, marking a turnaround from a net loss of ₹0.668 crore in the previous fiscal year. Consolidated net profit also saw an increase, reaching ₹2.08 crore from ₹0.846 crore in FY25. Alongside the financial results, the Board approved a significant capital expenditure of up to ₹100 crore for expanding its plant and machinery for manufacturing medical devices and healthcare products.

Why this matters

The reported profit turnaround on a standalone basis is a key positive for shareholders, indicating improved operational efficiency. The substantial capital expenditure plan signals the company's commitment to growth and capacity expansion in the healthcare and hygiene product segments. Changes in key leadership positions, like the CFO, and board reappointments are also noteworthy for corporate governance and future strategic direction.

The backstory

In the previous fiscal year (FY25), Nureca had reported a net loss on a standalone basis. The company has been focused on expanding its product portfolio within the healthcare and wellness sector. This recent announcement reflects a strategic push towards enhancing manufacturing capabilities.

What changes now

The approved ₹100 crore capex will be utilized for plant and machinery expansion at its existing site in Derabassi, Punjab, and for acquiring adjoining land. The company has also initiated a Scheme of Merger for its wholly-owned subsidiary, Nureca Technologies Private Limited, pending regulatory approvals. Mr. Naresh Gupta resigned as CFO, and Mr. Chander Kant has been appointed as the new CFO, effective June 27, 2026.

Risks to watch

Investors should be aware of the non-operating losses of ₹8.337 crore from fair value changes and net losses on investments, which impacted the consolidated bottom line. The transition of the CFO role requires monitoring for smooth operational continuity. The success of the capex execution and subsidiary merger will be critical.

Peer comparison

While specific peer financial data for FY26 is not provided in the filing, Nureca operates in the medical devices, healthcare consumables, and hygiene products sector. Companies in this segment often focus on R&D, manufacturing capacity, and market reach. Nureca's capex plan suggests a competitive move to scale up.

Context metrics (time-bound)

• Standalone Revenue FY26: ₹147.21 crore (vs ₹114.64 crore in FY25)
• Standalone Profit FY26: ₹0.297 crore (vs ₹-0.668 crore in FY25)
• Consolidated Revenue FY26: ₹146.963 crore (vs ₹109.661 crore in FY25)
• Consolidated Profit FY26: ₹2.08 crore (vs ₹0.846 crore in FY25)
• Capex Approval: Up to ₹100 crore
• CFO Change: Effective June 27, 2026
• Subsidiary Merger Filing: Proposed effective date April 1, 2025

What to track next

Investors will be keen to observe the progress of the ₹100 crore capex implementation, the finalization of the merger with Nureca Technologies Private Limited, and the performance under the new CFO. The company's ability to sustain profitability and manage investment-related fluctuations will be key.